Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Schure, Rose Minke ^a,b   de Rond, Lia ^a   Öztürk, Kemal ^a   Hendrikx, Lotte ^a   Sanders, Elisabeth ^b   Berbers, Guy ^a   Buisman, Anne Marie ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BOOSTRIX IPV; CYTOKINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENCE; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; CELLULAR IMMUNITY; CHILD; CHILDHOOD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EFFECTOR CELL; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; INCIDENCE; LONGITUDINAL STUDY; MEMORY CELL; PERTUSSIS; SCHOOL CHILD; TH1 CELL; TH17 CELL; TH2 CELL; VACCINATION;

ANTIGENS, CD3; ANTIGENS, CD4; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; NETHERLANDS; T-LYMPHOCYTES; WHOOPING COUGH;

EID: 84864459682     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041928     Document Type: Article

References (32)

1. Roush SW, Murphy TV, ((2007)) Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 298:: 2155--2163.
2. Pebody RG, Gay NJ, Giammanco A, Baron S, Schellekens J, et al. ((2005)) The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol Infect 133:: 159--171.
3. de Greeff SC, Schellekens JF, Mooi FR, de Melker HE, ((2005)) [Effect of vaccination against pertussis on the incidence of pertussis in The Netherlands, 1996-2003]. Ned Tijdschr Geneeskd 149:: 937--943.
4. de Greeff SC, Mooi FR, Schellekens JF, de Melker HE, ((2008)) Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J 27:: 218--223.
5. de Greeff SC, de Melker HE, van Gageldonk PG, Schellekens JF, van der Klis FR, et al. ((2010)) Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One 5:: e14183.
6. Healy CM, Rench MA, Baker CJ, ((2011)) Implementation of cocooning against pertussis in a high-risk population. Clin Infect Dis 52:: 157--162.
7. de Greeff SC, Mooi FR, Westerhof A, Verbakel JM, Peeters MF,et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 50:: 1339--1345.
8. Li WC, Wu TZ, Huang YC, Huang LM, ((2009)) Boostrix: a reduced-dose acellular pertussis vaccine for use in adolescents and adults. Expert Rev Vaccines 8:: 1317--1327.
9. Mills KHG, Ryan M, Ryan E, Mahon BP, ((1998)) A Murine Model in Which Protection Correlates with Pertussis Vaccine Efficacy in Children Reveals Complementary Roles for Humoral and Cell-Mediated Immunity in Protection against Bordetella pertussis. Infect Immun 66:: 594--602.
10. Hendrikx LH, Ozturk K, de Rond LG, Veenhoven RH, Sanders EA, et al. ((2011)) Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins. Vaccine 29:: 1431--1437.
11. Edelman K, He Q, Makinen J, Sahlberg A, Haanpera M, et al. ((2007)) Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 44:: 1271--1277.
12. Hendrikx LH, Felderhof MK, Ozturk K, de Rond LG, van Houten MA, et al. ((2011)) Enhanced memory B-cell immune responses after a second acellular pertussis booster vaccination in children 9 years of age. Vaccine 30:: 51--58.
13. Rieber N, Graf A, Hartl D, Urschel S, Belohradsky BH, et al. ((2011)) Acellular pertussis booster in adolescents induces Th1 and memory CD8+ T cell immune response. PLoS One 6:: e17271.
14. Hendrikx LH, de Rond LG, Ozturk K, Veenhoven RH, Sanders EA, et al. ((2011)) Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age. Vaccine 29:: 5725--5730.
15. Hendrikx LH, Berbers GA, Veenhoven RH, Sanders EA, Buisman AM, ((2009)) IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. Vaccine 27:: 6530--6536.
16. Loosmore SM, Yacoob RK, Zealey GR, Jackson GE, Yang YP, et al. ((1995)) Hybrid genes over-express pertactin from Bordetella pertussis. Vaccine 13:: 571--580.
17. Carollo M, Palazzo R, Bianco M, Smits K, Mascart F, et al. ((2012)) Antigen-specific responses assessment for the evaluation of Bordetella pertussis T cell immunity in humans. Vaccine 30:: 1667--1674.
18. Tran Minh NN, He Q, Ramalho A, Kaufhold A, Viljanen MK, et al. ((1999)) Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 104:: e70.
19. Pichichero ME, Casey JR, Francis AB, Marsocci SM, Murphy M, et al. ((2006)) Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules. Clin Pediatr (Phila) 45:: 613--620.
20. Edelman KJ, He Q, Makinen JP, Haanpera MS, Tran Minh NN, et al. ((2004)) Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis 39:: 179--185.
21. Van Damme P, McIntyre P, Grimprel E, Kuriyakose S, Jacquet JM, et al. ((2011)) Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix((R))) in adults 55 years of age and over: A sub-analysis of four trials. Vaccine.
22. Sanger R, Behre U, Krause KH, Loch HP, Soemantri P, et al. ((2007)) Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Eur J Pediatr 166:: 1229--1236.
23. Rieber N, Graf A, Belohradsky BH, Hartl D, Urschel S, et al. ((2008)) Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination. Vaccine 26:: 6929--6935.
24. Di Tommaso A, Bartalini M, Peppoloni S, Podda A, Rappuoli R, et al. ((1997)) Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults. Vaccine 15:: 1218--1224.
25. Darrah PA, Hegde ST, Patel DT, Lindsay RWB, Chen L, et al. ((2010)) IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. The Journal of Experimental Medicine 207:: 1421--1433.
26. Haynes L, Maue AC, ((2009)) Effects of aging on T cell function. Curr Opin Immunol 21:: 414--417.
27. Rohani P, Zhong X, King AA, ((2010)) Contact network structure explains the changing epidemiology of pertussis. Science 330:: 982--985.
28. Halperin SA, Scheifele D, Duval B, Law B, Ward B, et al. ((2005)) Canadian Association for Immunization Research and Evaluation (CAIRE) guidelines for industry-sponsored clinical trial and epidemiology contract research. Hum Vaccin 1:: 140--142.
29. de Greeff SC, Lugner AK, van den Heuvel DM, Mooi FR, de Melker HE, ((2009)) Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. Vaccine 27:: 1932--1937.
30. Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, et al. ((2007)) Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 26:: 293--299.
31. Berbers GA, de Greeff SC, Mooi FR, ((2009)) Improving pertussis vaccination. Hum Vaccin 5:: 497--503.
32. Rendi-Wagner P, Paulke-Korinek M, Stanek G, Khanakah G, Kollaritsch H, ((2007)) Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr Infect Dis J 26:: 806--810.